Latest Feed

CTO Summit 2019

28 feb-01 March 2019

Euro PCR 2019

21 May-24 may 2019

Optimal CTO 2019

Thursday 6 - Friday 7 June 2019

Royal College of Physicians, London

TCT 2019

24 Sept- 28th Sept 2019

New partnership with OrbusNeich...

NICC - 2018

6th Nordic Invasive Conference (NICC)

Aarhus, January 22-23, 2018

CTO summit 2018

Chronic Total Occlusion Summit 2018

A Live Case Demonstration Course

FEBRUARY 15-16, 2018

New York Marriott Marquis I 1535 Broadway I New York, NY

EuroPCR 2018

The World-Leading Course in Interventional Cardiovascular Medicine

22-25 May 2018

Palais des Congrès, Paris, France

TCT 2018

Transcatheter Cardiovascular Therapeutics (TCT) 2018

Sep 21 - 25, 2018 | San Diego, California

An effective percutaneous treatment for refractory angina, a severely debilitating condition that affects millions globally.

Resulting from inadequate blood flow to the heart muscle, refractory angina (RA) can often cause recurrent and severe heart pain that may be difficult to manage through conventional drug, catheter, or surgical therapy.  RA patients typically experience significant disability and impaired quality of life with few options for relief or improvement in their symptoms.

The Neovasc Reducer has been shown to be a safe and effective treatment for RA. Using a procedure similar to a coronary stent implantation, the Reducer procedure uses standard catheter-based techniques.

As with any medical procedure, there are risks associated with the use of the Neovasc Reducer™ System, including but not limited to myocardial infarction, continued angina, and implant migration/dislodgement requiring medical intervention. For a complete list of complications, see the Instructions for Use.


  • Treats a large and growing population of patients suffering from refractory angina who have limited options
  • Currently CE Marked
  • COSIRA data showed patients treated with Reducer were 2.3 times more likely to see an improvement of two Canadian Cardiovascular Society (CCS) functional classification as compared to the control arm (n = 104, p value = 0.024).
    Note: The CCS class is a functional classification used to stratify the severity of angina by evaluating angina symptoms with activity levels.
    N Eng J Med 2015;372:519-527

Euro PCR 16-19 May 2017

Step out of your daily work environment, the world is full of physicians similar to you. It is certainly rewarding to take a step back from the day-to-day grind and to share and debate your ideas.

Each year at EuroPCR partnerships are forged, research projects are born and career opportunities are created.

EuroPCR is a world in itself.


C.T.O Summit Feb 23-24, 2017

Leading practitioners of percutaneous coronary intervention must become experts at recanalizing chronic total occlusions (CTOs), and with advanced techniques, success rates greater than 90% may be obtained. Achieving high success rates with minimal complications is dependent upon physicians being up-to-date on the most recent advances in operator technique, guidewire technology, and other adjunctive devices.

Bringing together leaders in the field of CTOs, the Chronic Total Occlusion Summit: A Live Case Demonstration Course will be held in the heart of New York City.

Sessions will emphasize both advanced techniques and evidence-based medicine, with a heavy reliance on live case transmissions featuring the world’s leading experts in CTO PCI. Topics to be covered include:

  • Fundamentals of CTO PCI
  • Complex Retrograde and Antegrade CTO PCI
  • Complication Prevention and Management
  • How to Improve Outcomes Today
  • 2015 and 2016 Essential CTO Update
  • Live Case Transmissions
  • Edited Taped Case Presentations


PCI-dagarna 2016, Lund, Nov 17-18

Venue; Elite Hotel Ideon, Lund

Tema; PCI-gruppen VIC inbjuder traditionsenligt till PCI-dagarna 2016 som detta år går av stapeln i Lund.
Vi är stolta över att kunna presentera ett vetenskapligt program med föreläsare som David Erlinge, Göran Olivecrona, David Sparv (Zughaft) och Lennart Sandhall.
OBS! Anmälan nu öppen! Varmt välkommen till Lund



TCT 2016, Oct 29 – Nov 2

TCT 2016 is scheduled to commence Saturday, October 29 at 8:00 am ET and conclude on Wednesday, November 2 at 1:00 pm ET. The program is subject to change. Please visit TCT at a glance for the most current schedule



The Society (European Society of Minimally Invasive Neurological Therapy) and its Foundation (European Foundation of Minimally Invasive Neurological Therapy) have been established in order to promote the benefits of minimally invasive neurological therapies in Europe through education, training and support for high quality scientific research.

ESMINT encourages and supports medical practitioners and scientists working to develop and improve minimally invasive methods for the treatment of neurological diseases. These methods will naturally evolve and currently involve the use of image guidance and medical devices such as endovascular catheters to perform treatments with minimum associated trauma.

The Society and Foundation promote the safe application of such techniques and their practice by suitably trained and competent practitioners throughout Europe. ESMINT encourages the setting of international standards for practice and research and encourages their use and appropriate implementation.

The Society (ESMINT) consists of individuals and groups of members working or training in geographical Europe in the field of minimally invasive neurological therapy. The members will determine the organisational structure of the Society and they will be expected to aspire to the highest standards of ethical and scientific medical practice.


CIRSE 2016

Another great congress is on our doorstep, and we have done our utmost to ensure that it meets the high scientific standards expected by the CIRSE community.

Ever keen to improve and innovate, we’ve taken on board the feedback from last year in Lisbon, where the new IDEAS aortic symposium and the many venous sessions were warmly welcomed. Based on this enthusiastic response, the SPC has decided to repackage the vascular sessions into a comprehensive Endovascular Programme, which will be clearly stratified into three distinct categories: arterial interventions, venous interventions and aortic interventions, with the latter being presented within the framework of IDEAS 2016.

Special guests from other clinical specialties will again enrich our discussions, especially as part of the CIRSE meets the European Association of Urologists session, and within the Interdisciplinary Endovascular Aortic Symposium. IDEAS will be built upon, with additional session types and a hands-on Training Village, where visitors are free to try various devices and models for themselves.


Kära kollega och deltagare i Kardiovaskulära Vårmötet!

Som ordförande i organisationskommittén är det för mig en stor glädje att kunna presentera det vetenskapliga programmet för Svenska Hjärtförbundets 18:e Svenska Kardiovaskulära Vårmöte som äger rum 27-29 april på Svenska Mässan, Göteborg. Jag vill passa på att tacka alla som skickat in symposieförslag, vilket gjort att vi med Er hjälp även i år kan erbjuda ett program med både djup och bredd. Det preliminära programmet finns nu tillgängligt på hemsidan.

Our Partners